BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 30301812)

  • 21. Tumor-Infiltrating and Peripheral Blood T-cell Immunophenotypes Predict Early Relapse in Localized Clear Cell Renal Cell Carcinoma.
    Giraldo NA; Becht E; Vano Y; Petitprez F; Lacroix L; Validire P; Sanchez-Salas R; Ingels A; Oudard S; Moatti A; Buttard B; Bourass S; Germain C; Cathelineau X; Fridman WH; Sautès-Fridman C
    Clin Cancer Res; 2017 Aug; 23(15):4416-4428. PubMed ID: 28213366
    [No Abstract]   [Full Text] [Related]  

  • 22. MiR155 sensitized B-lymphoma cells to anti-PD-L1 antibody via PD-1/PD-L1-mediated lymphoma cell interaction with CD8+T cells.
    Zheng Z; Sun R; Zhao HJ; Fu D; Zhong HJ; Weng XQ; Qu B; Zhao Y; Wang L; Zhao WL
    Mol Cancer; 2019 Mar; 18(1):54. PubMed ID: 30925928
    [TBL] [Abstract][Full Text] [Related]  

  • 23. PD-1 Blockade Can Restore Functions of T-Cells in Epstein-Barr Virus-Positive Diffuse Large B-Cell Lymphoma In Vitro.
    Quan L; Chen X; Liu A; Zhang Y; Guo X; Yan S; Liu Y
    PLoS One; 2015; 10(9):e0136476. PubMed ID: 26361042
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Therapeutic vaccination against a murine lymphoma by intratumoral injection of a cationic anticancer peptide.
    Berge G; Eliassen LT; Camilio KA; Bartnes K; Sveinbjørnsson B; Rekdal O
    Cancer Immunol Immunother; 2010 Aug; 59(8):1285-94. PubMed ID: 20422410
    [TBL] [Abstract][Full Text] [Related]  

  • 25. CAR-T Cells Surface-Engineered with Drug-Encapsulated Nanoparticles Can Ameliorate Intratumoral T-cell Hypofunction.
    Siriwon N; Kim YJ; Siegler E; Chen X; Rohrs JA; Liu Y; Wang P
    Cancer Immunol Res; 2018 Jul; 6(7):812-824. PubMed ID: 29720380
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dendritic epidermal T cells in ultraviolet-irradiated skin enhance skin tumor growth by inhibiting CD4+ T-cell-mediated immunity.
    Cavanagh LL; Halliday GM
    Cancer Res; 1996 Jun; 56(11):2607-15. PubMed ID: 8653705
    [TBL] [Abstract][Full Text] [Related]  

  • 27. IL-2 intratumoral immunotherapy enhances CD8+ T cells that mediate destruction of tumor cells and tumor-associated vasculature: a novel mechanism for IL-2.
    Jackaman C; Bundell CS; Kinnear BF; Smith AM; Filion P; van Hagen D; Robinson BW; Nelson DJ
    J Immunol; 2003 Nov; 171(10):5051-63. PubMed ID: 14607902
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Autocrine Complement Inhibits IL10-Dependent T-cell-Mediated Antitumor Immunity to Promote Tumor Progression.
    Wang Y; Sun SN; Liu Q; Yu YY; Guo J; Wang K; Xing BC; Zheng QF; Campa MJ; Patz EF; Li SY; He YW
    Cancer Discov; 2016 Sep; 6(9):1022-35. PubMed ID: 27297552
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Identification of CD8+CD25+Foxp3+ suppressive T cells in colorectal cancer tissue.
    Chaput N; Louafi S; Bardier A; Charlotte F; Vaillant JC; Ménégaux F; Rosenzwajg M; Lemoine F; Klatzmann D; Taieb J
    Gut; 2009 Apr; 58(4):520-9. PubMed ID: 19022917
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phosphatidylserine-targeting antibodies augment the anti-tumorigenic activity of anti-PD-1 therapy by enhancing immune activation and downregulating pro-oncogenic factors induced by T-cell checkpoint inhibition in murine triple-negative breast cancers.
    Gray MJ; Gong J; Hatch MM; Nguyen V; Hughes CC; Hutchins JT; Freimark BD
    Breast Cancer Res; 2016 May; 18(1):50. PubMed ID: 27169467
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cord blood T cells mediate enhanced antitumor effects compared with adult peripheral blood T cells.
    Hiwarkar P; Qasim W; Ricciardelli I; Gilmour K; Quezada S; Saudemont A; Amrolia P; Veys P
    Blood; 2015 Dec; 126(26):2882-91. PubMed ID: 26450984
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Deficient tumor-infiltrating T-lymphocyte response in malignant lymphoma: relationship to HLA expression and host immunocompetence.
    List AF; Spier CM; Miller TP; Grogan TM
    Leukemia; 1993 Mar; 7(3):398-403. PubMed ID: 7680400
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A human programmed death-ligand 1-expressing mouse tumor model for evaluating the therapeutic efficacy of anti-human PD-L1 antibodies.
    Huang A; Peng D; Guo H; Ben Y; Zuo X; Wu F; Yang X; Teng F; Li Z; Qian X; Qin FX
    Sci Rep; 2017 Feb; 7():42687. PubMed ID: 28202921
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Herpes simplex virus (HSV) amplicon-mediated codelivery of secondary lymphoid tissue chemokine and CD40L results in augmented antitumor activity.
    Tolba KA; Bowers WJ; Muller J; Housekneckt V; Giuliano RE; Federoff HJ; Rosenblatt JD
    Cancer Res; 2002 Nov; 62(22):6545-51. PubMed ID: 12438249
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Robust Antitumor Effects of Combined Anti-CD4-Depleting Antibody and Anti-PD-1/PD-L1 Immune Checkpoint Antibody Treatment in Mice.
    Ueha S; Yokochi S; Ishiwata Y; Ogiwara H; Chand K; Nakajima T; Hachiga K; Shichino S; Terashima Y; Toda E; Shand FH; Kakimi K; Ito S; Matsushima K
    Cancer Immunol Res; 2015 Jun; 3(6):631-40. PubMed ID: 25711759
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Induction of hyperacute rejection of skin allografts by CD8+ lymphocytes.
    Yoshimura R; Chargui J; Aitouche A; Veyron P; Touraine JL
    Transplantation; 2000 Apr; 69(7):1452-7. PubMed ID: 10798770
    [TBL] [Abstract][Full Text] [Related]  

  • 37. T-bet and eomesodermin are required for T cell-mediated antitumor immune responses.
    Zhu Y; Ju S; Chen E; Dai S; Li C; Morel P; Liu L; Zhang X; Lu B
    J Immunol; 2010 Sep; 185(6):3174-83. PubMed ID: 20713880
    [TBL] [Abstract][Full Text] [Related]  

  • 38. CD103- and CD103+ bronchial lymph node dendritic cells are specialized in presenting and cross-presenting innocuous antigen to CD4+ and CD8+ T cells.
    del Rio ML; Rodriguez-Barbosa JI; Kremmer E; Förster R
    J Immunol; 2007 Jun; 178(11):6861-6. PubMed ID: 17513734
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Helper-independent, L-selectinlow CD8+ T cells with broad anti-tumor efficacy are naturally sensitized during tumor progression.
    Peng L; Kjaergaard J; Plautz GE; Weng DE; Shu S; Cohen PA
    J Immunol; 2000 Nov; 165(10):5738-49. PubMed ID: 11067932
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Anti-CD40-induced inflammatory E-cadherin+ dendritic cells enhance T cell responses and antitumour immunity in murine Lewis lung carcinoma.
    Zhang Y; Hu X; Hu Y; Teng K; Zhang K; Zheng Y; Hong X; Yu K; Wang Y; Liu L
    J Exp Clin Cancer Res; 2015 Feb; 34(1):11. PubMed ID: 25651850
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.